...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR.
【24h】

Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR.

机译:通过多重等位基因特异性PCR测定的七个不同人群中的凝血酶原G20210A,V G1691A因子(Leiden)和亚甲基四氢叶酸还原酶(MTHFR)C677T的患病率。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Individuals belonging to six racial groups (African American, Asian Indian, Caucasian, Hispanic, Korean, Native American), and a seventh group comprised of referred patients with thrombosis were genotyped for the prothrombin G20210A mutation, the factor V G1691A (Leiden) mutation, and the methylenetetrahydrofolate reductase (MTHFR) C677T mutation by multiplexed allele-specific PCR. The prothrombin 20210A and factor V 1691A allele frequencies in the thrombosis patients, 3.2% and 9.5%, were significantly higher than those in the random Caucasians, 1.3% and 1.8%, (p = 0.043 and p <0.001, respectively). The relative risk of venous thrombosis was determined to be 2.4-fold for carriers of the prothrombin 20210A allele (odds ratio = 2.54; 95% confidence interval = 0.94, 6.82) and 4.5-fold for carriers of the factor V 1691A allele (odds ratio = 5.06; 95% confidence interval = 2.25, 11.36). Among the seven populations, significant differences were observed in the MTHFR 677T allele distribution, however this mutation was not determined to be a risk factor for venous thrombosis in the patient group studied, either alone or in combination with the prothrombin 20210A and/or the factor V 1691A allele(s).
机译:对属于血栓形成转诊患者的六个种族组(非裔美国人,亚洲印第安人,白种人,西班牙裔,韩国人,印第安人)和第七组的个体进行凝血酶原G20210A突变,V G1691A因子(Leiden)突变,多重等位基因特异性PCR检测亚甲基四氢叶酸还原酶(MTHFR)C677T突变。血栓形成患者的凝血酶原20210A和因子V 1691A等位基因频率分别为3.2%和9.5%,显着高于随机白种人的1.3%和1.8%(分别为p = 0.043和p <0.001)。凝血酶原20210A等位基因携带者的静脉血栓形成相对风险被确定为2.4倍(几率= 2.54; 95%置信区间= 0.94、6.82),因子V 1691A等位基因携带者的静脉血栓形成的相对风险为4.5倍(几率= 5.06; 95%置信区间= 2.25,11.36)。在这七个人群中,在MTHFR 677T等位基因分布中观察到了显着差异,但是,在所研究的患者组中,单独或与凝血酶原20210A和/或该因子联合使用,均未将该突变确定为静脉血栓形成的危险因素。 V 1691A等位基因。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号